{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T22:13:58Z","timestamp":1769120038938,"version":"3.49.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2017,7,31]],"date-time":"2017-07-31T00:00:00Z","timestamp":1501459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>BACKGROUND<\/jats:title>\n                  <jats:p>Visit-to-visit blood pressure variability has been associated with adverse cardiovascular outcomes. Using the SPRINT trial data set, we explored the relationship between blood pressure variability, cardiovascular outcomes, and hypoperfusion-related adverse events of antihypertensive therapy in patients with chronic kidney disease (CKD) enrolled in the study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>The analyses included patients with CKD randomized in SPRINT who reached the target systolic blood pressure for their respective groups (intensive &amp;lt;120 mm Hg; standard &amp;lt;140 mm Hg). Coefficients of variation (CV) for diastolic blood pressure (DBP) for each subject characterized variability. Cox proportional hazards regression was used to identify independent predictors of the SPRINT primary outcome (including acute coronary syndrome, stroke, acute heart failure, and death from cardiovascular causes) and the 3 major side effects of therapy\u2014hypotension, syncope, and acute kidney injury (AKI). P &amp;lt;0.15 on univariate analysis was required to enter the model, and P &amp;lt;0.05 to remain in it.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Overall, 2,488 subjects (1,273 standard; 1,124 intensive) met inclusion criteria. DBP CV predicted a greater hazard for primary outcome (hazard ratio [HR] 1.126, P &amp;lt; 0.0001) in the overall model as well as in separate analyses by treatment arms (standard group HR 1.107, P &amp;lt; 0.0001; intensive group HR 1.100, P = 0.0004). DBP CV also independently predicted a greater hazard for AKI (HR 1.117), syncope (HR 1.111), and hypotensive events (HR 1.104).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSION<\/jats:title>\n                  <jats:p>Visit-to-visit DBP variability independently predicts worse cardiovascular outcomes and hypoperfusion-related adverse events in patients with CKD enrolled in SPRINT.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajh\/hpx128","type":"journal-article","created":{"date-parts":[[2017,7,11]],"date-time":"2017-07-11T12:42:26Z","timestamp":1499776946000},"page":"48-52","source":"Crossref","is-referenced-by-count":20,"title":["Blood Pressure Variability Predicts Adverse Events and Cardiovascular Outcomes in Chronic Kidney Disease: A Post-Hoc Analysis of the SPRINT Trial"],"prefix":"10.1093","volume":"31","author":[{"given":"Kenechukwu","family":"Mezue","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Einstein Medical Center, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhinav","family":"Goyal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Einstein Medical Center, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregg S","family":"Pressman","sequence":"additional","affiliation":[{"name":"Heart and Vascular Institute, Division of Cardiology, Einstein Medical Center, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay C","family":"Horrow","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Perioperative Medicine, Drexel University College of Medicine, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janani","family":"Rangaswami","sequence":"additional","affiliation":[{"name":"Department of Medicine, Einstein Medical Center, USA"},{"name":"Sidney Kimmel College of Thomas Jefferson University, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,7,31]]},"reference":[{"key":"2022111809293076500_CIT0001","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(05)17741-1","article-title":"Global burden of hypertension: analysis of worldwide data","volume":"365","author":"Kearney","year":"2005","journal-title":"Lancet"},{"key":"2022111809293076500_CIT0002","first-page":"e28","article-title":"Heart disease and stroke statistics\u20132014 update: a report from the American Heart Association","volume":"129","author":"Go","year":"2014","journal-title":"Circulation"},{"key":"2022111809293076500_CIT0003","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1093\/eurheartj\/ehr003","article-title":"Renal function and target organ damage in hypertension","volume":"32","author":"Ruilope","year":"2011","journal-title":"Eur Heart J"},{"key":"2022111809293076500_CIT0004","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/ki.2010.292","article-title":"National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events","volume":"78","author":"Bakris","year":"2010","journal-title":"Kidney Int"},{"key":"2022111809293076500_CIT0005","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","article-title":"Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies","volume":"360","author":"Lewington","year":"2002","journal-title":"Lancet"},{"key":"2022111809293076500_CIT0006","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension"},{"key":"2022111809293076500_CIT0007","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1161\/HYPERTENSIONAHA.114.03903","article-title":"Visit-to-visit variability of blood pressure and cardiovascular disease and all-cause mortality: a systematic review and meta-analysis","volume":"64","author":"Diaz","year":"2014","journal-title":"Hypertension"},{"key":"2022111809293076500_CIT0008","doi-asserted-by":"crossref","first-page":"i4098","DOI":"10.1136\/bmj.i4098","article-title":"Blood pressure variability and cardiovascular disease: systematic review and meta-analysis","volume":"354","author":"Stevens","year":"2016","journal-title":"BMJ"},{"key":"2022111809293076500_CIT0009","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"key":"2022111809293076500_CIT0010","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Cushman","year":"2010","journal-title":"N Engl J Med"},{"key":"2022111809293076500_CIT0011","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"2022111809293076500_CIT0012","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/HJH.0000000000000779","article-title":"Visit-to-visit variability of blood pressure and death, end-stage renal disease, and cardiovascular events in patients with chronic kidney disease","volume":"34","author":"Chang","year":"2016","journal-title":"J Hypertens"},{"key":"2022111809293076500_CIT0013","doi-asserted-by":"crossref","first-page":"4404","DOI":"10.1093\/ndt\/gfs328","article-title":"Blood pressure variability and outcomes in chronic kidney disease","volume":"27","author":"Di Iorio","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2022111809293076500_CIT0014","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.atherosclerosis.2011.07.111","article-title":"Arterial stiffness and 24 h ambulatory blood pressure monitoring in young healthy volunteers: the early vascular ageing Aristotle University Thessaloniki Study (EVA-ARIS Study)","volume":"219","author":"Kotsis","year":"2011","journal-title":"Atherosclerosis"},{"key":"2022111809293076500_CIT0015","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1291\/hypres.31.2137","article-title":"Awake blood pressure variability, inflammatory markers and target organ damage in newly diagnosed hypertension","volume":"31","author":"Tatasciore","year":"2008","journal-title":"Hypertens Res"},{"key":"2022111809293076500_CIT0016","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11906-013-0328-5","article-title":"Sympathetic hyperactivity in chronic kidney disease: pathophysiology and (new) treatment options","volume":"15","author":"Vink","year":"2013","journal-title":"Curr Hypertens Rep"},{"key":"2022111809293076500_CIT0017","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/01.hco.0000240587.14463.58","article-title":"Treatment of hypertension based on measurement of blood pressure variability: lessons from animal studies","volume":"21","author":"Su","year":"2006","journal-title":"Curr Opin Cardiol"},{"key":"2022111809293076500_CIT0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MNH.0b013e32835b36c1","article-title":"Renal microvascular dysfunction, hypertension and CKD progression","volume":"22","author":"Bidani","year":"2013","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2022111809293076500_CIT0019","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0140-6736(10)60235-8","article-title":"Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis","volume":"375","author":"Webb","year":"2010","journal-title":"Lancet"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/31\/1\/48\/47108101\/ajh_31_1_48.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/31\/1\/48\/47108101\/ajh_31_1_48.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T09:30:48Z","timestamp":1668763848000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/31\/1\/48\/4056349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,31]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,7,31]]},"published-print":{"date-parts":[[2018,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpx128","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"value":"0895-7061","type":"print"},{"value":"1941-7225","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,1]]},"published":{"date-parts":[[2017,7,31]]}}}